U
Eloxx Pharmaceuticals, Inc.
ELOX
$0.0001
$0.000.00%
E
Sell
12/20/2024Downgrade
Eloxx Pharmaceuticals, Inc. (ELOX) was downgraded to E+ from D- on 12/20/2024 due to a noticeable decline in the volatility index and total return index.
Eloxx Pharmaceuticals, Inc. (ELOX) was downgraded to E+ from D- on 12/20/2024 due to a noticeable decline in the volatility index and total return index.
D
Sell
12/4/2024Upgraded
Eloxx Pharmaceuticals, Inc. (ELOX) was upgraded to D- from E+ on 12/4/2024 due to a noticeable increase in the volatility index.
Eloxx Pharmaceuticals, Inc. (ELOX) was upgraded to D- from E+ on 12/4/2024 due to a noticeable increase in the volatility index.
E
Sell
11/19/2024Downgrade
Eloxx Pharmaceuticals, Inc. (ELOX) was downgraded to E+ from D- on 11/19/2024 due to a noticeable decline in the volatility index.
Eloxx Pharmaceuticals, Inc. (ELOX) was downgraded to E+ from D- on 11/19/2024 due to a noticeable decline in the volatility index.
D
Sell
10/9/2024Upgraded
Eloxx Pharmaceuticals, Inc. (ELOX) was upgraded to D- from E+ on 10/9/2024 due to an increase in the volatility index.
Eloxx Pharmaceuticals, Inc. (ELOX) was upgraded to D- from E+ on 10/9/2024 due to an increase in the volatility index.
E
Sell
9/24/2024Downgrade
Eloxx Pharmaceuticals, Inc. (ELOX) was downgraded to E+ from D- on 9/24/2024 due to a decline in the volatility index.
Eloxx Pharmaceuticals, Inc. (ELOX) was downgraded to E+ from D- on 9/24/2024 due to a decline in the volatility index.
D
Sell
9/9/2024Upgraded
Eloxx Pharmaceuticals, Inc. (ELOX) was upgraded to D- from E+ on 9/9/2024 due to a substantial increase in the valuation index and volatility index.
Eloxx Pharmaceuticals, Inc. (ELOX) was upgraded to D- from E+ on 9/9/2024 due to a substantial increase in the valuation index and volatility index.
E
Sell
9/29/2023Downgrade
Eloxx Pharmaceuticals, Inc. (ELOX) was downgraded to E+ from D- on 9/29/2023 due to a decline in the volatility index.
Eloxx Pharmaceuticals, Inc. (ELOX) was downgraded to E+ from D- on 9/29/2023 due to a decline in the volatility index.
D
Sell
9/14/2023Upgraded
Eloxx Pharmaceuticals, Inc. (ELOX) was upgraded to D- from E+ on 9/14/2023 due to an increase in the volatility index.
Eloxx Pharmaceuticals, Inc. (ELOX) was upgraded to D- from E+ on 9/14/2023 due to an increase in the volatility index.
E
Sell
7/27/2023Downgrade
Eloxx Pharmaceuticals, Inc. (ELOX) was downgraded to E+ from D- on 7/27/2023 due to a decline in the volatility index and valuation index.
Eloxx Pharmaceuticals, Inc. (ELOX) was downgraded to E+ from D- on 7/27/2023 due to a decline in the volatility index and valuation index.
D
Sell
7/12/2023Upgraded
Eloxx Pharmaceuticals, Inc. (ELOX) was upgraded to D- from E+ on 7/12/2023 due to an increase in the volatility index and total return index.
Eloxx Pharmaceuticals, Inc. (ELOX) was upgraded to D- from E+ on 7/12/2023 due to an increase in the volatility index and total return index.
E
Sell
3/14/2023Downgrade
Eloxx Pharmaceuticals, Inc. (ELOX) was downgraded to E+ from D on 03/14/2023.
Eloxx Pharmaceuticals, Inc. (ELOX) was downgraded to E+ from D on 03/14/2023.
D
Sell
2/9/2023Upgraded
Eloxx Pharmaceuticals, Inc. (ELOX) was upgraded to D from E+ on 02/09/2023.
Eloxx Pharmaceuticals, Inc. (ELOX) was upgraded to D from E+ on 02/09/2023.
E
Sell
2/8/2023Downgrade
Eloxx Pharmaceuticals, Inc. (ELOX) was downgraded to E+ from D on 2/8/2023 due to a decline in the total return index.
Eloxx Pharmaceuticals, Inc. (ELOX) was downgraded to E+ from D on 2/8/2023 due to a decline in the total return index.
D
Sell
1/5/2023Upgraded
Eloxx Pharmaceuticals, Inc. (ELOX) was upgraded to D from D- on 1/5/2023 due to an increase in the volatility index.
Eloxx Pharmaceuticals, Inc. (ELOX) was upgraded to D from D- on 1/5/2023 due to an increase in the volatility index.
D
Sell
12/6/2022Downgrade
Eloxx Pharmaceuticals, Inc. (ELOX) was downgraded to D- from D on 12/6/2022 due to a decline in the volatility index.
Eloxx Pharmaceuticals, Inc. (ELOX) was downgraded to D- from D on 12/6/2022 due to a decline in the volatility index.
D
Sell
11/21/2022Upgraded
Eloxx Pharmaceuticals, Inc. (ELOX) was upgraded to D from D- on 11/21/2022 due to an increase in the valuation index, growth index and volatility index. EBIT increased 30.63% from -$10.3M to -$7.14M, earnings per share increased from -$0.1225 to -$0.0866, and operating cash flow increased 28.74% from -$9.75M to -$6.95M.
Eloxx Pharmaceuticals, Inc. (ELOX) was upgraded to D from D- on 11/21/2022 due to an increase in the valuation index, growth index and volatility index. EBIT increased 30.63% from -$10.3M to -$7.14M, earnings per share increased from -$0.1225 to -$0.0866, and operating cash flow increased 28.74% from -$9.75M to -$6.95M.
D
Sell
8/15/2022Upgraded
Eloxx Pharmaceuticals, Inc. (ELOX) was upgraded to D- from E+ on 8/15/2022 due to a noticeable increase in the growth index. Earnings per share increased from -$0.1341 to -$0.1225, and EBIT increased 6% from -$10.95M to -$10.3M.
Eloxx Pharmaceuticals, Inc. (ELOX) was upgraded to D- from E+ on 8/15/2022 due to a noticeable increase in the growth index. Earnings per share increased from -$0.1341 to -$0.1225, and EBIT increased 6% from -$10.95M to -$10.3M.
E
Sell
6/22/2022Downgrade
Eloxx Pharmaceuticals, Inc. (ELOX) was downgraded to E+ from D- on 6/22/2022 due to a decline in the volatility index.
Eloxx Pharmaceuticals, Inc. (ELOX) was downgraded to E+ from D- on 6/22/2022 due to a decline in the volatility index.
D
Sell
5/6/2022Upgraded
Eloxx Pharmaceuticals, Inc. (ELOX) was upgraded to D- from E+ on 5/6/2022 due to an increase in the growth index and total return index. EBIT increased 5.82% from -$11.63M to -$10.95M, operating cash flow increased 4.43% from -$9.93M to -$9.49M, and earnings per share increased from -$0.1397 to -$0.1341.
Eloxx Pharmaceuticals, Inc. (ELOX) was upgraded to D- from E+ on 5/6/2022 due to an increase in the growth index and total return index. EBIT increased 5.82% from -$11.63M to -$10.95M, operating cash flow increased 4.43% from -$9.93M to -$9.49M, and earnings per share increased from -$0.1397 to -$0.1341.
E
Sell
4/18/2022Downgrade
Eloxx Pharmaceuticals, Inc. (ELOX) was downgraded to E+ from D on 4/18/2022 due to a major decline in the growth index, solvency index and volatility index. Debt to equity increased from 0.49 to 0.73, operating cash flow declined 30.88% from -$7.59M to -$9.93M, and EBIT declined 23.13% from -$9.45M to -$11.63M.
Eloxx Pharmaceuticals, Inc. (ELOX) was downgraded to E+ from D on 4/18/2022 due to a major decline in the growth index, solvency index and volatility index. Debt to equity increased from 0.49 to 0.73, operating cash flow declined 30.88% from -$7.59M to -$9.93M, and EBIT declined 23.13% from -$9.45M to -$11.63M.
D
Sell
2/24/2022Upgraded
Eloxx Pharmaceuticals, Inc. (ELOX) was upgraded to D from D- on 2/24/2022 due to an increase in the volatility index.
Eloxx Pharmaceuticals, Inc. (ELOX) was upgraded to D from D- on 2/24/2022 due to an increase in the volatility index.
D
Sell
2/8/2022Downgrade
Eloxx Pharmaceuticals, Inc. (ELOX) was downgraded to D- from D on 2/8/2022 due to a decline in the volatility index and total return index.
Eloxx Pharmaceuticals, Inc. (ELOX) was downgraded to D- from D on 2/8/2022 due to a decline in the volatility index and total return index.
D
Sell
1/18/2022Upgraded
Eloxx Pharmaceuticals, Inc. (ELOX) was upgraded to D from D- on 1/18/2022 due to an increase in the volatility index.
Eloxx Pharmaceuticals, Inc. (ELOX) was upgraded to D from D- on 1/18/2022 due to an increase in the volatility index.
D
Sell
1/3/2022Downgrade
Eloxx Pharmaceuticals, Inc. (ELOX) was downgraded to D- from D on 1/3/2022 due to a decline in the volatility index and total return index.
Eloxx Pharmaceuticals, Inc. (ELOX) was downgraded to D- from D on 1/3/2022 due to a decline in the volatility index and total return index.
D
Sell
12/13/2021Upgraded
Eloxx Pharmaceuticals, Inc. (ELOX) was upgraded to D from D- on 12/13/2021 due to an increase in the volatility index.
Eloxx Pharmaceuticals, Inc. (ELOX) was upgraded to D from D- on 12/13/2021 due to an increase in the volatility index.
D
Sell
11/26/2021Downgrade
Eloxx Pharmaceuticals, Inc. (ELOX) was downgraded to D- from D on 11/26/2021 due to a decline in the volatility index and total return index.
Eloxx Pharmaceuticals, Inc. (ELOX) was downgraded to D- from D on 11/26/2021 due to a decline in the volatility index and total return index.
D
Sell
11/10/2021Upgraded
Eloxx Pharmaceuticals, Inc. (ELOX) was upgraded to D from E+ on 11/10/2021 due to a major increase in the growth index. Earnings per share increased from -$0.5431 to -$0.1147, operating cash flow increased 22.55% from -$9.8M to -$7.59M, and EBIT increased 21.55% from -$13.06M to -$10.25M.
Eloxx Pharmaceuticals, Inc. (ELOX) was upgraded to D from E+ on 11/10/2021 due to a major increase in the growth index. Earnings per share increased from -$0.5431 to -$0.1147, operating cash flow increased 22.55% from -$9.8M to -$7.59M, and EBIT increased 21.55% from -$13.06M to -$10.25M.
E
Sell
11/8/2021Downgrade
Eloxx Pharmaceuticals, Inc. (ELOX) was downgraded to E+ from D- on 11/8/2021 due to a noticeable decline in the growth index, total return index and volatility index. Earnings per share declined from -$0.2164 to -$0.5431, EBIT declined 55.21% from -$8.41M to -$13.06M, and operating cash flow declined 27.48% from -$7.69M to -$9.8M.
Eloxx Pharmaceuticals, Inc. (ELOX) was downgraded to E+ from D- on 11/8/2021 due to a noticeable decline in the growth index, total return index and volatility index. Earnings per share declined from -$0.2164 to -$0.5431, EBIT declined 55.21% from -$8.41M to -$13.06M, and operating cash flow declined 27.48% from -$7.69M to -$9.8M.
D
Sell
5/17/2021Downgrade
Eloxx Pharmaceuticals, Inc. (ELOX) was downgraded to D- from D on 5/17/2021 due to a decline in the growth index, solvency index and valuation index. Debt to equity increased from 1.25 to 5.15, operating cash flow declined 64.63% from -$4.67M to -$7.69M, and EBIT declined 45.52% from -$5.78M to -$8.41M.
Eloxx Pharmaceuticals, Inc. (ELOX) was downgraded to D- from D on 5/17/2021 due to a decline in the growth index, solvency index and valuation index. Debt to equity increased from 1.25 to 5.15, operating cash flow declined 64.63% from -$4.67M to -$7.69M, and EBIT declined 45.52% from -$5.78M to -$8.41M.
D
Sell
6/23/2020Upgraded
Eloxx Pharmaceuticals, Inc. (ELOX) was upgraded to D from D- on 6/23/2020 due to an increase in the growth index, total return index and volatility index.
Eloxx Pharmaceuticals, Inc. (ELOX) was upgraded to D from D- on 6/23/2020 due to an increase in the growth index, total return index and volatility index.
D
Sell
5/11/2020Downgrade
Eloxx Pharmaceuticals, Inc. (ELOX) was downgraded to D- from D on 5/11/2020 due to a decline in the valuation index, solvency index and growth index. Debt to equity increased from 0.42 to 0.56, operating cash flow declined 28.81% from -$9.26M to -$11.92M, and earnings per share declined from -$0.291 to -$0.348.
Eloxx Pharmaceuticals, Inc. (ELOX) was downgraded to D- from D on 5/11/2020 due to a decline in the valuation index, solvency index and growth index. Debt to equity increased from 0.42 to 0.56, operating cash flow declined 28.81% from -$9.26M to -$11.92M, and earnings per share declined from -$0.291 to -$0.348.
D
Sell
5/1/2020Upgraded
Eloxx Pharmaceuticals, Inc. (ELOX) was upgraded to D from D- on 5/1/2020 due to an increase in the valuation index, volatility index and solvency index.
Eloxx Pharmaceuticals, Inc. (ELOX) was upgraded to D from D- on 5/1/2020 due to an increase in the valuation index, volatility index and solvency index.
D
Sell
1/23/2020Upgraded
Eloxx Pharmaceuticals, Inc. (ELOX) was upgraded to D- from E+ on 1/23/2020 due to an increase in the total return index, volatility index and valuation index.
Eloxx Pharmaceuticals, Inc. (ELOX) was upgraded to D- from E+ on 1/23/2020 due to an increase in the total return index, volatility index and valuation index.
E
Sell
12/17/2019Downgrade
Eloxx Pharmaceuticals, Inc. (ELOX) was downgraded to E+ from D- on 12/17/2019 due to a decline in the valuation index.
Eloxx Pharmaceuticals, Inc. (ELOX) was downgraded to E+ from D- on 12/17/2019 due to a decline in the valuation index.
D
Sell
11/29/2019Upgraded
Eloxx Pharmaceuticals, Inc. (ELOX) was upgraded to D- from E+ on 11/29/2019 due to an increase in the valuation index and volatility index.
Eloxx Pharmaceuticals, Inc. (ELOX) was upgraded to D- from E+ on 11/29/2019 due to an increase in the valuation index and volatility index.
E
Sell
11/13/2019Downgrade
Eloxx Pharmaceuticals, Inc. (ELOX) was downgraded to E+ from D- on 11/13/2019 due to a decline in the total return index, valuation index and solvency index. Debt to equity increased from 0.27 to 0.33, and the quick ratio declined from 6.94 to 5.82.
Eloxx Pharmaceuticals, Inc. (ELOX) was downgraded to E+ from D- on 11/13/2019 due to a decline in the total return index, valuation index and solvency index. Debt to equity increased from 0.27 to 0.33, and the quick ratio declined from 6.94 to 5.82.
D
Sell
10/3/2019Upgraded
Eloxx Pharmaceuticals, Inc. (ELOX) was upgraded to D- from E+ on 10/3/2019 due to an increase in the valuation index.
Eloxx Pharmaceuticals, Inc. (ELOX) was upgraded to D- from E+ on 10/3/2019 due to an increase in the valuation index.
E
Sell
9/18/2019Downgrade
Eloxx Pharmaceuticals, Inc. (ELOX) was downgraded to E+ from D- on 9/18/2019 due to a noticeable decline in the volatility index, total return index and solvency index.
Eloxx Pharmaceuticals, Inc. (ELOX) was downgraded to E+ from D- on 9/18/2019 due to a noticeable decline in the volatility index, total return index and solvency index.
D
Sell
9/4/2018Upgraded
Eloxx Pharmaceuticals, Inc. (ELOX) was upgraded to D- from E on 9/4/2018 due to an increase in the total return index.
Eloxx Pharmaceuticals, Inc. (ELOX) was upgraded to D- from E on 9/4/2018 due to an increase in the total return index.
E
Sell
8/17/2018Downgrade
Eloxx Pharmaceuticals, Inc. (ELOX) was downgraded to E from E+ on 8/17/2018 due to a noticeable decline in the growth index, volatility index and efficiency index. EBIT declined 111.15% from -$6.49M to -$13.71M, net income declined 56.05% from -$8.59M to -$13.41M, and operating cash flow declined 49.39% from -$5.7M to -$8.51M.
Eloxx Pharmaceuticals, Inc. (ELOX) was downgraded to E from E+ on 8/17/2018 due to a noticeable decline in the growth index, volatility index and efficiency index. EBIT declined 111.15% from -$6.49M to -$13.71M, net income declined 56.05% from -$8.59M to -$13.41M, and operating cash flow declined 49.39% from -$5.7M to -$8.51M.
E
Sell
6/5/2018Upgraded
Eloxx Pharmaceuticals, Inc. (ELOX) was upgraded to E+ from E on 6/5/2018 due to an increase in the total return index and valuation index.
Eloxx Pharmaceuticals, Inc. (ELOX) was upgraded to E+ from E on 6/5/2018 due to an increase in the total return index and valuation index.
E
Sell
5/25/2018None
Eloxx Pharmaceuticals, Inc. (ELOX) was downgraded to E from U on 05/25/2018.
Eloxx Pharmaceuticals, Inc. (ELOX) was downgraded to E from U on 05/25/2018.
OTC PK
04/09/2025 3:21PM Eastern
Quotes delayed
